Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2

Cancer Research

Volumn 61, Issue 3, 2001, Pages 859-863

  Mendiratta, Sanjeev Kumar ^a   Thai, Gerald ^a   Eslahi, Nima K ^a   Thull, Nikolyn M ^a   Matar, Majed ^a   Bronte, Vincenzo ^b   Pericle, Federica ^a  

^a Urigen Pharmaceuticals Inc   (United States)

^b Department of Oncology and Surgical Sciences ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; RECOMBINANT GAMMA INTERFERON; RNA; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ELECTROPORATION; IMMUNE RESPONSE; IMMUNIZATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; ELECTROPORATION; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINES, COMBINED;

EID: 0035113524     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy
2. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
3. T-cell apoptosis detected in situ during positive and negative selection in the thymus
4. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
5. An autologous oral DNA vaccine protects against murine melanoma
6. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells
7. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
8. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
9. DNA vaccines: Immunology, application, and optimization
10. Polyvinyl derivatives as novel interactive polymers controlled gene delivery to muscle
11. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
12. Fundamentals of electroporative delivery of drugs and genes
13. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo
14. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
15. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
16. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent anti-tumor immunity
17. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
18. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
19. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
20. Coupling and uncoupling of tumor immunity and autoimmunity
21. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy
22. Bleomycin-mediated electrochemotherapy of metastatic melanoma
23. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes
24. The immunogenicity of single and combination DNA vaccines against tuberculosis